A biography of arsenic and medicine in Hong Kong and China

Hong Kong Medical Journal

Volumn 17, Issue 6, 2011, Pages 507-513

  Au, W Y ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDOTE; ARSENIC; ARSENIC DERIVATIVE; ARSENIC SULPHIDE; ARSENIC TRIOXIDE; ARSENOL; MELARSOPROL; POTASSIUM ARSENITE; RETINOIC ACID; UNCLASSIFIED DRUG;

ANEMIA; ARSENIC POISONING; ARTICLE; ASCITES; BLEEDING; CHINA; CHINESE MEDICINE; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; FILARIASIS; HEMATOLOGIC MALIGNANCY; HONG KONG; HUMAN; LEISHMANIASIS; LEUKEMIA; LEUKOCYTOSIS; LIVER CANCER; MAINTENANCE THERAPY; NONHUMAN; PARASITOSIS; PATENT; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; SCHISTOSOMIASIS; SPLENOMEGALY; SYPHILIS; TRADITIONAL MEDICINE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TRYPANOSOMIASIS; WEIGHT GAIN; WESTERN MEDICINE;

ARSENIC; CHINA; HISTORY, 16TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HONG KONG; HUMANS; MEDICINE, CHINESE TRADITIONAL;

EID: 83255184552     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Chen SJ, Zhou GB, Zhang XW, Mao JH, de Thé H, Chen Z. From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 2011;117:6425-37.
2. Cullen WR. Is arsenic an aphrodisiac? The social biochemistry of an element. Cambridge: Royal Society of Chemistry; 2008.
3. Fowler T. Medical report of the effect of arsenic in the cure of agues, remitting fevers and periodic headaches. London: Johnson and Brown; 1786.
4. Scheindlin S. The duplicitous nature of inorganic arsenic. Mol Interv 2005;5:60-4.
5. Lissauer. Zwei Falle von Leucaemie. Berl Klin Wochenschr 1865;2:403-4.
6. Doyle D. The Maclagan family: six generations of service. J R Coll Physicians Edinb 2010;40:178-84.
7. Baumer E. In search of the magic bullet. London: Thames and Hudson publishers; 1965.
8. Wintrobe MM. Two contemporary hematologists: Claude Forkner and William Moloney. Haematology, the blossoming of a science. Lea and Febiger; 1985: 110-5.
9. Forkner CE, Scott MT. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931;97:3-5.
10. Haut A, Altman SJ, Cartwright GE, Wintrobe MM. The use of myleran in the treatment of chronic myeloid leukemia. JAMA 1951;145:166-70.
11. Höfer R, Mannheimer E, Reimer EE, Vetter H. Treatment of chronic myeloid leukemia with colloidal radiogold (Au 198). Nucl Med (Stuttg) 1963;2(Suppl 1):389S-398S.
12. Lai KK, Chan JL, Lai KK, Schmer G, Fritsche TR. Sir Patrick Manson: good medicine for the people of Hong Kong. Hong Kong Med J 2003;9:145-7.
13. Cantlie J. Some tropical diseases and the remedies required for their treatment and prophylaxis: notes on a demonstration. Proc R Soc Med 1908;1(Ther Pharmacol Sect):22-8.
14. Ng LN. The Hong Kong origins of Dr Sun Yat-Sen's address to Li Hung Chang. J Royal Asiatic Soc Hong Kong Branch 1981;21:168-78.
15. Sun YS. Kidnapped in London. London; J.W. Arrowsmith: 1897.
16. Obituary: Sir Halliday Macartney. BMJ 1906;1:1442-3.
17. Smyly HJ. The medical situation in China. Lancet 1926;207:946-7.
18. Hata S. The present status and future problems of chemotherapy. Concorde, New Hampshire: Dedication Ceremonies and Medical Conference, Peking Union Medical Center Rumford Press; 1921: 248-64.
19. Formulary of the Peking Union Medical College. Peking: PUMC Press; 1927: 1-67.
20. Faust EC. Schistosomiasis in China: biological and practical aspects. Proc R Soc Med 1924;17(Sect Trop Dis Parasitol):31-43.
21. Forkner CE. Clinical and pathological aspects of acute leukemia. Bull N Y Acad Med 1939;15:377-91.
22. Evans DE. The first crisis-Rockefeller and salvation. Constancy of Purpose. Faculty of Medicine of the University of Hong Kong. Hong Kong: Hong Kong University Press; 1987: 61-70.
23. Yu YL. Reminiscences of three former teachers: Prof AJS McFadzean, Dr Stephen Chang and Prof Gerald Choa. Hong Kong Med J 2009;15:315-8.
24. Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 1997;89:3487-8.
25. Budavari S. Arsenic trioxide. The Merck Index 11th ed. Rahway, NJ. 1989: 127.
26. Meng Z, Yang P, Shen Y, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 2009;115:5309-18.
27. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223-46.
28. Zhang TD, Sun HD, Hu HX. Treatment of acute promyelocytic leukemia with Ailing number one combination therapy: a study of 73 cases [in Chinese]. Heilongjiang Journal of Traditional Chinese Medicine 1981;4:40-4.
29. Zhang TD, Li YX. Clinical research and laboratory analysis on the treatment of acute promyelocytic leukemia with Ailing number 1 solution [in Chinese]. Journal of Combined Chinese and Western Therapy 1984;4:19-20.
30. Ma J. Advances in management of acute promyelocytic leukemia with arsenic trioxide. Chin J Integr Med 2007;13:92-4.
31. Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002;99:3136-43.
32. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
33. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990;347:558-61.
34. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
35. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-24.
36. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052-61.
37. Wang ZY. Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis. Hematology Am Soc Hematol Educ Program 2003:1-13.
38. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339:1341-8.
39. Cyranoski D. Arsenic patent keeps drug for rare cancer out of reach of many. Nat Med 2007;13:1005.
40. Warrell RP Jr. Reply to 'Arsenic patent keeps drug for rare cancer out of reach for many'. Nat Med 2007;13:1278.
41. Mathews V, George B, Chendamarai E, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010;28:3866-71.
42. Ghavamzadeh A, Alimoghaddam K, Rostami S, et al. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 2011;29:2753-7.
43. Ribeiro RC, Rego E. Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program 2006:162-8.
44. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. Am J Hematol 2001;66:274-9.
45. Vogel AI. Determination of arsenates. A textbook of quantitative inorganic analysis. Oxford: Pergamon; 1939: 332-4.
46. Kumana CR, Au WY, Lee NS, et al. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 2002;58:521-6.
47. Siu CW, Au WY, Yung C, et al. Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 2006;108:103-6.
48. Au WY, Kumana CR, Kou M, et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003;102:407-8.
49. Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004;101:5328-35.
50. Hu J, Liu YF, Wu CF, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009;106:3342-7.
51. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010;116:3751-7.
52. Au WY, Chim CS, Lie AK, Liang R, Kwong YL. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide. Br J Haematol 2002;117:130-2.
53. Au WY, Lie AK, Chim CS, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003;14:752-7.
54. Versitech. On going project on humanitarian perspectives. http://www.versitech.hku.hk/arsenol/human.htm. Accessed 2011 Jul 27.
55. Sun G. Arsenic contamination and arsenicosis in China. Toxicol Appl Pharmacol 2004;198:268-71.